Mineralys Therapeutics is on the verge of a major milestone as their drug lorundrostat heads toward FDA approval with a PDUFA date set for December 22nd. The company is ramping up commercial readiness, building its sales team, and engaging payers to ensure broad access. Strategically, they’ve locked in $400 million in financing — including a $200M royalty buyback, $150M equity raise, and $250M term loan — to fuel launch prep. Clinical data from trials like Transform HTN and LAUNCH-HTN continues to impress, showing strong blood pressure control even in hard-to-treat patients with kidney disease, plus promising signals for heart failure risk reduction. New CMO Dr. Terry Ferguson brings deep cardiovascular expertise to lead the charge, while former CMO Dr. David Rodman transitions to strategic advisory. With a clear path forward, Mineralys is poised to make a big impact in uncontrolled hypertension — and exploring partnerships to extend reach.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
